UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2025 | $19.50 | Neutral → Buy | Compass Point |
| 12/12/2024 | $19.50 → $21.50 | Mkt Perform → Outperform | Keefe Bruyette |
| 1/16/2024 | $17.00 → $17.50 | Buy → Neutral | Compass Point |
| 11/21/2023 | $17.00 | Neutral | UBS |
| 8/30/2023 | $17.50 | Neutral → Buy | Compass Point |
| 8/4/2023 | $13.50 → $17.00 | Underperform → Mkt Perform | Keefe Bruyette |
| 4/6/2023 | $16.00 | Neutral → Overweight | Piper Sandler |
| 3/13/2023 | $14.50 → $10.50 | Mkt Perform → Underperform | Keefe Bruyette |
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
Compass Point upgraded Hercules Capital from Neutral to Buy and set a new price target of $19.50
Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously
Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2025 financial results conference call for Thursday, February 12, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Re
-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI -- Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity. Under the terms of the amended loan agreement, up to an additional $75 million will become available upon FDA's approval of MOLBREEVI, the Company's investigational therapy in autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The loan agreement maturity d
Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer $25 million advanced at close of the amendment to refinance existing debt facility enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the "Loan Agreement") with two of its subsidiaries and Hercules Capital, Inc. (NYSE:HTGC) ("Hercules"), as agent, for up to US$125 million. Access to the additional non-dilutive capital strengthens enGene's
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
40-17G - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
10-Q - Hercules Capital, Inc. (0001280784) (Filer)
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2025 financial results conference call for Thursday, February 12, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Re
Q3 2025 Total New Debt and Equity Commitments of $846.2 Million Record Q3 2025 Total Fundings of $504.6 Million Record Year-to-Date Ending Q3 2025 Total Debt and Equity Commitments of $2.87 Billion Record Year-to-Date Ending Q3 2025 Total Fundings of $1.75 Billion Record Q3 2025 Total Investment Income of $138.1 Million Q3 2025 Net Investment Income "NII" of $88.6 Million Q3 2025 NII of $0.49 per Share provides 122% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net GAAP Leverage of 98.2% and Net Regulatory Leverage of 82.3%(1) Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-owned Subsidiary, Hercules had over $1.
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its third quarter 2025 financial results conference call for Thursday, October 30, 2025, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Resources section
Strategic growth financing accelerates expansion through acquisition and supports product innovation Snappt, the leading platform for applicant trust in multifamily housing, today announced it has acquired Trigo, a company known for its breakthrough technology in verifying rental payment history. Backed by a $50 million committed facility from Hercules Capital, Inc. (NYSE:HTGC), the acquisition expands Snappt's platform and strengthens its ability to help property managers make faster, more confident leasing decisions. Together, these milestones mark a major step toward building the industry's most complete and trusted solution embedded into the application and screening process. "This
SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc
SC 13G - Hercules Capital, Inc. (0001280784) (Subject)
SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)
SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)